Reata Pharmaceuticals, Inc. Appoints Geoffrey A. Block, M.D. as Vice President, Nephrology

NASDAQ Market News

NEXT STORY
Spero Therapeutics Announces Positive Feedback from FDA Pre-Phase 3 Meeting for Oral SPR994 and Submission of IND for SPR994 in cUTI
PREV STORY
ADMA Biologics Submits Response and Provides Supplemental Information to FDA for BIVIGAM® Complete Response Letter
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

FibroGen Announces Early Phase 2 Data From a Clinical Study of FG-3019 in Combination With Chemotherapy as Neoadjuvant in Locally Advanced, Unresectable Pancreatic Cancer

SAN FRANCISCO, Jan. 27, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (FibroGen) today announced early ...

author_avatar
NASDAQ Market News

Idera Pharmaceuticals Announces Private Placement Up To $97.7 Million

author_avatar
NASDAQ Market News

Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

author_avatar
NASDAQ Market News